Navigation Links
American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
Date:2/22/2012

SHIRLEY, N.Y., Feb. 22, 2012 /PRNewswire/ -- American Regent is conducting a nationwide voluntary recall to the Retail/Hospital level of the following product:

Phenylephrine HCl Injection, USP, 1% (10mg/mL), 5 mL Vial
NDC # 0517-0405-25, Lot # 0693, Exp Date: October, 2012.

PLEASE NOTE:  This recall, initiated on February 22, 2012 to the Retail/Hospital Level, is for Lot # 0693 only.  No other lots or sizes of Phenylephrine HCl Injection, USP are subject to this voluntary recall.

American Regent is undertaking this voluntary recall of Phenylephrine HCl Injection, USP, Lot 0693 due to potential safety concerns stemming from the identification of visible particles found in some retained samples of this lot. American Regent has not received any reports of adverse events related to this recall.

Potential adverse events after intravenous administration of solutions containing particulates may include disruption of blood flow within small blood vessels in the lung, localized inflammation (swelling and redness), and granuloma formation.

Phenylephrine HCl Injection, USP is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anesthesia and for the treatment of vascular failure in shock, shock like states, and drug-induced hypotension, or hypersensitivity. It is also employed to overcome paroxysmal supraventricular tachycardia, to prolong spinal anesthesia, and as a vasoconstrictor in regional analgesia.

The product was distributed to wholesalers and distributors nationwide.

Hospitals, Emergency Rooms, Clinics, and other healthcare facilities and providers should not use American Regent, Inc., Phenylephrine HCl Injection, USP, 1% (10mg/mL), 5 mL Vials, with Lot #0693, for patient care and should immediately quarantine any product for return.

American Regent is notifying its distributors and consumers by e-mail, facsimile and/or overnight courier and is arranging for return of all recalled product.  Consumers/distributors/retailers that have product which is being recalled should stop use.

American Regent will credit accounts for all returned Phenylephrine HCl Injection, USP, 1% (10mg/mL), 5 mL Vials, with Lot # 0693. Those with questions about the return or recall process, please call our Customer Service Department at 1- 800-645-1706: Monday thru Friday from 8:30 AM to 7:00 PM ET.

Hospitals, emergency rooms, clinics, and other healthcare facilities and providers, or patients with product quality complaints, medical or other questions concerning the use of the product or reasons for this recall should contact the Professional Services Department at 1-877-788-3232: Monday thru Friday from  9:00 AM to 5:00 PM ET.

Any adverse reactions experienced with the use of this product should be reported to American Regent, Inc. via e-mail at pv@luitpold.com by fax to (610) 650-0170, or by phone at 1-800-734-9236: Monday thru Friday from 9:00 AM to 5 PM ET.  TO EXPEDITE HANDLING PLEASE DO NOT REPORT ANYTHING OTHER THAN SPECIFIC ADVERSE EVENTS TO THIS E-MAIL ADDRESS OR FAX OR PHONE.

Adverse reactions or quality problems experienced with the use of this product/lot may be reported to the FDA's MedWatch Adverse Event Reporting program online, by regular mail or by fax.

While American Regent continues to investigate this issue, the company is taking precautionary action and initiated this voluntary recall.  American Regent has informed the FDA of its actions and is maintaining ongoing discussions with the agency.

As is standard practice, "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."

Phenylephrine HCl Injection, USP is manufactured by Luitpold Pharmaceuticals, Inc. and is distributed by American Regent, Inc. (Shirley, NY).

This voluntary recall is being conducted with the knowledge of the U.S. Food and Drug Administration.


'/>"/>
SOURCE Luitpold Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Aspirin Named 8th World Wonder by Majority of Americans
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
8. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
9. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  The goal of the ... identify and track prescription drugs as they are distributed ... response to requirements from US FDA to better protect ... dangerous medicines. Blockchain startup Chronicled, which ... chips and blockchain technology and recently raised $6.25M, and ...
(Date:3/23/2017)... 2017 The global reprocessed ... the top five players accounting for nearly 94% ... are Stryker Sustainability Solutions, Ethicon (Johnson & Johnson), ... VANGUARD AG. Despite the high level of consolidation, ... the prevalence of fierce competition among the key ...
(Date:3/23/2017)... -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) today ... Phase 1 study of MM-310 in solid tumors. MM-310 ... taxane and targets the EphA2 receptor, a protein which ... tumor types, including prostate, ovarian, bladder, gastric, pancreatic and ... is an important step in evaluating MM-310,s safety and ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... VoiceAmerica, recently talked on her program about how she is looking forward to World ... of an important distinction. World Water Day, Kleyne pointed out, is an occasion for ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... ... 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce a ... solid foundation. As experts in dangerous situations the Inflow IQ team can help ... deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance and Utilization ... ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , It is ... the association, but also to the Health Care Quality and Patient Safety movements. Diplomates ...
Breaking Medicine News(10 mins):